Related references
Note: Only part of the references are listed.Cancer Statistics, 2009
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2009)
Prostate stem cell antigen: A prospective therapeutic and diagnostic target
Adam B. Raff et al.
CANCER LETTERS (2009)
Target-dependent T-cell Activation by Coligation With a PSMA×CD3 Diabody Induces Lysis of Prostate Cancer Cells
Patrick Bühler et al.
JOURNAL OF IMMUNOTHERAPY (2009)
Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells
Sandrine d'Argouges et al.
LEUKEMIA RESEARCH (2009)
Advances in specific immunotherapy for prostate cancer
Andrea Kiessling et al.
EUROPEAN UROLOGY (2008)
Tumor regression in cancer patients by very low doses of a T cell-engaging antibody
Ralf Bargou et al.
SCIENCE (2008)
A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells
P. Buehler et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2008)
Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T-cells
Agnieszka Morgenroth et al.
PROSTATE (2007)
Targeting, imaging, and therapy using a humanized antiprostate stem cell antigen (PSCA) antibody
Tove Olafsen et al.
JOURNAL OF IMMUNOTHERAPY (2007)
CD19/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis
Michael Molhoj et al.
MOLECULAR IMMUNOLOGY (2007)
Monoclonal antibody-based therapeutics for leukemia
Yiwen Li et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2007)
Tissue-specificity of prostate specific antigens: Comparative analysis of transcript levels in prostate and non-prostatic tissues
Ana C. Cunha et al.
CANCER LETTERS (2006)
Antibody-based therapeutics: Focus on prostate cancer
JS Ross et al.
CANCER AND METASTASIS REVIEWS (2005)
Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific antibody construct
B Schlereth et al.
CANCER RESEARCH (2005)
Monoclonal antibody therapy of cancer
GP Adams et al.
NATURE BIOTECHNOLOGY (2005)
Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: Long-term results
KA Roehl et al.
JOURNAL OF UROLOGY (2004)
Androgen deprivation therapy for prostate cancer: Current status and future prospects
H Miyamoto et al.
PROSTATE (2004)
Induction of human T lymphocyte cytotoxicity and inhibition of tumor growth by tumor-specific diabody-based molecules secreted from gene-modified bystander cells
B Blanco et al.
JOURNAL OF IMMUNOLOGY (2003)
T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3-bispecific single-chain antibody construct
T Dreier et al.
JOURNAL OF IMMUNOLOGY (2003)
Radical radiation for localized prostate cancer: Local persistence of disease results in a late wave of metastases
JJ Coen et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
The development of androgen-independent prostate cancer
BJ Feldman et al.
NATURE REVIEWS CANCER (2001)
Bispecific and bifunctional single chain recombinant antibodies
J Kriangkum et al.
BIOMOLECULAR ENGINEERING (2001)
Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts
DC Saffran et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer
Z Gu et al.
ONCOGENE (2000)
Universal PCR amplification of mouse immunoglobulin gene variable regions:: the design of degenerate primers and an assessment of the effect of DNA polymerase 3′ to 5′ exonuclease activity
ZD Wang et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2000)
Share Paper
